We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
The drug asundexian (Bayer) received FDA priority status for preventing recurrent stroke. Risk reduction of 26% without increased bleeding. Details of the OCEANIC-STROKE study.
